Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of renal allograft with current actinic keratosis I or II or successfully treated actinic keratosis III (inclusion possible immediately after completed wound healing from surgical excision), invasive squamous cell carcinoma (SCC), basal cell carcinoma~* age 18 years and older~* minimum period of 6 month after renal transplantation~* stable renal function and a calculated creatinine clearance of at least 40 ml/min~* written informed consent~* proteinuria ≤ 800 mg/d at time of enrolment~* successfully treated solid tumor (no recurrence or metastasis in the last 2 years)~Exclusion Criteria:~* Current Sirolimus- or Everolimus- intake~* Instable graft function (creatinine clearance \< 40 ml/min)~* Graft rejection within the 3 previous months~* Proteinuria \> 800 mg/d~* Non-controlled hyperlipidemia (Cholesterol \>7,8 mmol/l (300 mg/dl), Triglycerides \> 4 mmol/l (350 mg/dl)~* Leucopenia \< 2500/nl~* Thrombocytopenia \< 90/nl~* Pregnancy or breastfeeding~* Women of childbearing age without highly effective contraception~* Known allergy to macrolides~* Current participation in other studies~* Refusal to sign informed consent form~* Neoplasm other than defined as inclusion criteria~* All contraindications to SRL (see package insert, appendix)~* Persons who are detained officially or legally to an official institute~* Acute infections (mycotic, viral or bacterial)~* Current intake of other substances with known nephrotoxicity~* Severe liver dysfunction~* Current intake of CY3A4-inhibitors (e.g. ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or CY3A4-inductors (rifampicin, rifabutin)~* sucrose-isomaltase deficiency, fructose intolerance, glucose-galactose intolerance~* azathioprine: known allergy to azathioprine or 6-mercaptopurine, severe bone marrow dysfunction, pancreatitis, vaccination with live vaccine~* tacrolimus: known allergy to tacrolimus~* mycophenolatmofetil: known allergy to mycophenolatmofetil, neutropenia, severe active gastrointestinal tract disease, Lesch-Nyhan syndrome or Kelley-Seegmiller syndrome, current intake of azathioprine~* cyclosporine: known allergy to cyclosporine, increased intracranial pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: ACTIVE_COMPARATOR): Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
- Standard therapy (Type: NO_INTERVENTION): Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).